Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck ...

According to Bladder Cancer UK, the main symptoms of bladder cancer are: ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

What are the symptoms of bladder cancer – and how is it treated? - The most common symptom of bladder cancer is blood in your ...